Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Today’s headlines highlight critical developments in genetic medicine, global politics, and the latest updates from the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

16 In the future, CRISPR diagnostics have the potential to transform the field of personalized medicine. By enabling the rapid and precise identification of genetic predispositions, these tools ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...